Double-Blind Placebo-Controlled Study Comparing the Combination of 15% SP-303 Gel With Acyclovir Versus Acyclovir Alone for the Treatment of Recurrent Herpes Simplex Virus (HSV) Infections in Subjects With Acquired Immunodeficiency Syndrome (AIDS)
Sponsor: Shaman Pharmaceuticals
Listed as NCT00002186, this NA trial focuses on HIV Infections and Herpes Simplex and remains completed. Sponsored by Shaman Pharmaceuticals, it has been updated 6 times since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2021 — Jul 2024 [monthly]
Completed NA
-
Jun 2018 — Jan 2021 [monthly]
Completed NA
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Shaman Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Altamonte Springs, United States, Arlington, United States, Austin, United States, Baltimore, United States, Birmingham, United States, Boston, United States, Chicago, United States, Dallas, United States, Fort Lauderdale, United States, Fort Myers, United States and 18 more location s